These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38012065)

  • 1. Sodium-glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure.
    Karlström P; Pivodic A; Dahlström U; Fu M
    ESC Heart Fail; 2024 Feb; 11(1):327-337. PubMed ID: 38012065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
    Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
    Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
    ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
    Hu WS; Lin CL
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study.
    Park S; Jeong HE; Lee H; You SC; Shin JY
    Cardiovasc Diabetol; 2023 Jul; 22(1):191. PubMed ID: 37507739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
    Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
    Eur J Heart Fail; 2023 Sep; 25(9):1648-1658. PubMed ID: 37419495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure.
    Kanaoka K; Iwanaga Y; Nakai M; Nishioka Y; Myojin T; Kubo S; Okada K; Noda T; Sakata Y; Miyamoto Y; Saito Y; Imamura T
    Eur Heart J Cardiovasc Pharmacother; 2023 Jul; 9(5):444-452. PubMed ID: 37173281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
    Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer.
    Chiang CH; Chiang CH; Chiang CH; Ma KS; Peng CY; Hsia YP; Horng CS; Chen CY; Chang YC; See XY; Chen YJ; Wang SS; Suero-Abreu GA; Peterson LR; Thavendiranathan P; Armand P; Peng CM; Shiah HS; Neilan TG
    Heart; 2023 Feb; 109(6):470-477. PubMed ID: 36351793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter 2 Inhibitors in South Australia: The Magic Before the Fame.
    Tan JY; Chew DP; Lambrakis K; Tiver KD; Gnanamanickam ES; Muthuranjan C; Stranks SN; De Pasquale CG
    Heart Lung Circ; 2023 Nov; 32(11):1369-1377. PubMed ID: 37914540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.